Pfizer’s Prevnar vs Merck’s Pneumovax — Which Company Gets A Bigger Shot In the Arm?

by Trefis Team
+41.65%
Upside
36.91
Market
52.29
Trefis
PFE
Pfizer
Rate   |   votes   |   Share

Pfizer (NYSE:PFE) and Merck (NYSE:MRK) both participate in the pneumonia vaccination market, and both cater to different age groups. Pneumonia refers to lung inflammation caused by bacterial or viral infection. Pfizer’s Prevnar is the leader in the pneumonia drugs market. Prevnar and Merck’s Pneumovax are the two key drugs used as a vaccination to protect against Pneumonia. Prevnar is usually given to infants at the age of 2, 4, and 6 months, while Pneumovax is recommended for adults aged 65 years and older. Prevnar garnered sales of close to $5.8 billion in 2018. This compares with sales of under $1 billion for Merck’s Pneumovax. Pfizer is developing a 20-valent pneumonia vaccine candidate, which has shown positive preliminary results in the phase 2 trials. If approved, it will be successor of the current Prevnar 13 vaccine. In this note we compare the performance of these two drugs. You can view our interactive dashboard analysis ~ How Does Pfizer Fare In Pneumonia Vaccines Market? ~ for more details.  In addition, you can see more of our data for Healthcare companies here.

Pfizer’s Prevnar Is The Top Selling Vaccine For Pneumonia, Followed By Merck’s Pneumovax

  • Prevnar sales have increased from $4.5 billion in 2014 to $5.8 billion in 2018.
  • Pneumovax sales have increased from $746 million in 2014 to $907 million in 2018.

Combined Sales of Pneumonia Vaccines Above Grew From $5.2 Billion In 2014 To $6.7 Billion In 2018. Prevnar’s Share Hovered Around 86% During The Same Period, And It Could Decline Slightly In The Coming Years, As Any Significant Growth In Vaccine Sales Is Unlikely

Prevnar Is One of The Top Selling Drugs For Pfizer, And It Accounts For Over 10% of The Company’s Total Sales

Looking At Population Trend, Total No. of Births In The U.S. Are On A Decline, While There Is A Growth In Adults Population of Age Over 65 Years, And This Trend Could Continue

What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs

For CFOs and Finance Teams | Product, R&D, and Marketing Teams

More Trefis Data

Like our charts? Explore example interactive dashboards and create your own.

Rate   |   votes   |   Share

Comments

Name (Required)
Email (Required, but never displayed)
Be the first to comment!